Tilray | TRLY - Equity Capital And Reserves


Tilray reported $1.58B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acasti Pharma USD 64.89M 2.07M Dec/2025
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Avita Medical AUD -16.65M 3.76M Dec/2025
Canopy Growth CAD 697.59M 60.58M Mar/2026
Cronos Group USD 1.07B 4.99M Jun/2026
Dianthus Therapeutics USD 1.17B 29.29M Jun/2026
Divis Laboratories Ltd INR 167.61B 13.48B Mar/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
IQVIA Holdings USD 6.17B 50M Jun/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Moderna USD 6.76B 647M Jun/2026
Organigram Holdings CAD 371.81M 2.36M Mar/2026
Organon & Co USD 903M 151M Mar/2026
Revvity USD 7.18B 67.62M Mar/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Tilray USD 1.58B 39.08M Sep/2025
Viatris USD 14.66B 53.6M Mar/2026
Xeris Pharmaceuticals USD -9.73M 22.74M Jun/2026
Zealand Pharma A/S 14.47B 361.61M Mar/2026